Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"Accesswire • 12/15/21
Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia TrialBenzinga • 11/23/21
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid LeukemiaAccesswire • 11/23/21
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual MeetingAccesswire • 11/15/21
Aptevo Therapeutics Reports Third Quarter Financial Results With Business HighlightsAccesswire • 11/12/21
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021Accesswire • 11/11/21
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual MeetingAccesswire • 11/11/21
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021Accesswire • 10/27/21
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436Accesswire • 10/26/21
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in AgingAccesswire • 09/28/21
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeAccesswire • 08/17/21
Aptevo Therapeutics Reports Second Quarter Financial Results with Business HighlightsAccesswire • 08/12/21
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual ConferenceAccesswire • 07/16/21
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?Zacks Investment Research • 06/15/21
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid LeukemiaAccesswire • 05/27/21
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia PatientsBenzinga • 05/26/21
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid LeukemiaAccesswire • 05/26/21
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual MeetingAccesswire • 04/09/21